No abstract

Background A meta-analysis of previously performed evaluation studies of nucleic acid amplification testing (NAT) approaches for the screening for and differentiation of Plasmodium spp. using identical samples was performed to comparatively assess their suitability for the routine diagnostic setting. Methods Three commercial NATs for malaria (one loop-mediated isothermal amplification [LAMP] assay, two real-time polymerase chain reactions [PCRs]) and one in-house real-time PCR were comparatively assessed with a collection of 1020 well-characterized ethylenediaminetetraacetic acid (EDTA) blood samples from patients with suspected or confirmed malaria. Results Altogether 765 (75%) concordantly negative and 223 (21.9%) concordantly positive results of the four molecular tests were obtained, while discordant results were seen in 32 (3.1%) instances. For genus-specific assays, the observed sensitivity and specificity ranges were 96.4%–98.4% and 99.6%–99.9%, and for species-specific assays, 94.0%–97.6% and 99.6%–100%, respectively. Falsely negative molecular test results comprised microscopically negative samples, samples at the microscopic detection threshold and quantitatively less abundant species in mixed infections. Conclusions Excellent test characteristics of all assessed assays with only minor differences encourage molecular malaria screening with genus- and species-specific NAT with discrepancies only within the borderline range of their detection thresholds.

Background: Mongolia has a high prevalence of Helicobacter pylori infection and gastric cancer. We conducted a prospective, randomized, single-blind study to evaluate the efficacy of common regimens in Mongolia and to obtain specimens for susceptibility testing. Methods: Empiric treatments: 270 patients with confirmed H. pylori infection were randomized to receive 10 days clarithromycin-triple therapy (Clari-TT) ( n = 90), modified bismuth quadruple therapy (M-BQT) ( n = 90), or sequential therapy (ST) ( n = 90). A second group of 46 patients received susceptibility-based Clari-TT. H. pylori was cultured from 131 patients and susceptibility testing was performed. H. pylori eradication was confirmed by stool antigen 4 weeks after the therapy. Results: Intention-to-treat (ITT) analysis cure rates were 71.1% (95% CI = 61.7–80.5%) for Clari-TT, 87.8% (95% CI = 81–94.6%) for M-BQT, 67.8% (95% CI = 58.1–77.5%) for ST vs. 89.1% (95% CI = 86–98.2%) for susceptibility-based Clari-TT. Per-protocol (PP) analysis results for these therapies were 72.7% (63.4–82%), 89.8% (83.5–96.1%), 68.5% (58.8–78.2%), and 97.6% (89.5–99.8%), respectively. Among 131 cultured H. pylori , resistance rates to amoxicillin, clarithromycin, and metronidazole were 8.4, 37.4, and 74%, respectively. Conclusion: In Mongolia, the prevalence of H. pylori resistance is high requiring bismuth quadruple therapy or susceptibility-based therapy to obtain acceptable cure rates.

Abstract. Immediately before deployment (Fall 2012) and after deployment (Spring 2013) in support of United Nations peacekeeping operations, Mongolian Armed Forces medical personnel obtained serum samples from the first contingent of Mongolian peacekeepers deploying to South Sudan to monitor serologic evidence of exposure to diseases that cause acute febrile illness. A total of 632 paired samples were tested for IgG antibody for the following (number of seroconversions in parentheses): Rickettsia (spotted fever and typhus groups) (25), West Nile fever virus (WNV) (23), Coxiella burnetii (causative agent of Q fever) (12), dengue virus (8